Cover Image
市場調查報告書

高度惡性神經膠質瘤的開發中產品分析

High-Grade Glioma - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 271830
出版日期 內容資訊 英文 333 Pages
訂單完成後即時交付
價格
Back to Top
高度惡性神經膠質瘤的開發中產品分析 High-Grade Glioma - Pipeline Review, H2 2017
出版日期: 2017年12月29日 內容資訊: 英文 333 Pages
簡介

高度惡性神經膠質瘤(HGG)是中樞神經系統(CNS)的腫瘤,發病於腦·脊椎的惡性轉換細胞。主要的症狀為發育遲緩和頭痛·背痛、噁心·嘔吐、暈眩、步行障礙、視力降低、集中力降低、睡意、睡眠障礙、不規則的食慾、麻痺·癲癇等。主要的治療方法有化療和放射治療等。

本報告提供全球各國治療量等級神經膠質瘤(Glioma)用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

高度惡性神經膠質瘤(Glioma)概要

治療藥的開發

  • 高度惡性神經膠質瘤開發中產品:概要
  • 高度惡性神經膠質瘤開發中產品:比較分析

各企業開發中的高度惡性神經膠質瘤治療藥

大學/研究機關研究中的高度惡性神經膠質瘤治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

高度惡性神經膠質瘤治療藥:開發中的產品一覽(各企業)

高度惡性神經膠質瘤治療藥:研究中的產品一覽(大學/研究機關別)

高度惡性神經膠質瘤治療藥的開發企業

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Bayer AG
  • Virttu Biologics Limited
  • AngioChem Inc.
  • Stemline Therapeutics, Inc.
  • TAU Therapeutics, LLC
  • Tocagen Inc.
  • AROG Pharmaceuticals LLC

高度惡性神經膠質瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • nintedanib
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ANG-1005
  • ANG-1005
  • (dabrafenib + trametinib)
  • Gene Therapy for High-Grade Glioma and Liver Transplantation
  • Dendritic Cell Vaccine
  • sorafenib tosylate
  • vocimagene amiretrorepvec + flucytosine ER
  • SL-701
  • crenolanib besylate
  • mibefradil dihydrochloride
  • GDC-0084
  • HSV-1716
  • TBX-01
  • Toca- RNAi

高度惡性神經膠質瘤治療藥:開發中產品的最新趨勢

高度惡性神經膠質瘤治療藥:暫停開發的產品

高度惡性神經膠質瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全2件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10016IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 15, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High-Grade Glioma - Overview
    • High-Grade Glioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • High-Grade Glioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • High-Grade Glioma - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Advenchen Laboratories LLC
    • AngioChem Inc
    • Arog Pharmaceuticals Inc
    • Astellas Pharma Inc
    • Athenex Inc
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Co
    • Cavion LLC
    • CBT Pharmaceuticals Inc
    • Celgene Corp
    • Concordia International Corp
    • DelMar Pharmaceuticals Inc
    • Eisai Co Ltd
    • Ipsen SA
    • Karyopharm Therapeutics Inc
    • Millennium Pharmaceuticals Inc
    • Nektar Therapeutics
    • Northwest Biotherapeutics Inc
    • Novartis AG
    • Ono Pharmaceutical Co Ltd
    • Sanofi
    • Sorrento Therapeutics Inc
    • Sumitomo Dainippon Pharma Co Ltd
    • Targepeutics Inc
    • Tocagen Inc
    • ZIOPHARM Oncology Inc
  • High-Grade Glioma - Drug Profiles
    • AdRTSIL-12 - Drug Profile
    • afatinib dimaleate - Drug Profile
    • alisertib - Drug Profile
    • apatinib mesylate - Drug Profile
    • bendamustine hydrochloride - Drug Profile
    • BMX-001 - Drug Profile
    • cabazitaxel - Drug Profile
    • CBT-101 - Drug Profile
    • Cellular Immunotherapy for High-Grade Glioma - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • crenolanib besylate - Drug Profile
    • dabrafenib mesylate - Drug Profile
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
    • DCVax-L - Drug Profile
    • depatuxizumab mafodotin - Drug Profile
    • dianhydrogalactitol - Drug Profile
    • elatipepimut-S + adegrapepimut-S - Drug Profile
    • etirinotecan pegol - Drug Profile
    • flucytosine + TBio-01 - Drug Profile
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    • GB-13 - Drug Profile
    • HSV-1716 - Drug Profile
    • ipilimumab + nivolumab - Drug Profile
    • irinotecan hydrochloride - Drug Profile
    • irinotecan hydrochloride + TBio-02 - Drug Profile
    • KX-02 - Drug Profile
    • lenvatinib mesylate - Drug Profile
    • mibefradil dihydrochloride - Drug Profile
    • nivolumab - Drug Profile
    • ONC-206 - Drug Profile
    • Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile
    • paclitaxel trevatide - Drug Profile
    • pomalidomide - Drug Profile
    • porfimer sodium - Drug Profile
    • RRX-001 - Drug Profile
    • selinexor - Drug Profile
    • sorafenib tosylate - Drug Profile
    • z-90099 - Drug Profile
  • High-Grade Glioma - Dormant Projects
  • High-Grade Glioma - Discontinued Products
  • High-Grade Glioma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for High-Grade Glioma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • High-Grade Glioma - Pipeline by AbbVie Inc, H2 2017
  • High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2017
  • High-Grade Glioma - Pipeline by AngioChem Inc, H2 2017
  • High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H2 2017
  • High-Grade Glioma - Pipeline by Astellas Pharma Inc, H2 2017
  • High-Grade Glioma - Pipeline by Athenex Inc, H2 2017
  • High-Grade Glioma - Pipeline by Bayer AG, H2 2017
  • High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • High-Grade Glioma - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • High-Grade Glioma - Pipeline by Cavion LLC, H2 2017
  • High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H2 2017
  • High-Grade Glioma - Pipeline by Celgene Corp, H2 2017
  • High-Grade Glioma - Pipeline by Concordia International Corp, H2 2017
  • High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
  • High-Grade Glioma - Pipeline by Eisai Co Ltd, H2 2017
  • High-Grade Glioma - Pipeline by Ipsen SA, H2 2017
  • High-Grade Glioma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
  • High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • High-Grade Glioma - Pipeline by Nektar Therapeutics, H2 2017
  • High-Grade Glioma - Pipeline by Northwest Biotherapeutics Inc, H2 2017
  • High-Grade Glioma - Pipeline by Novartis AG, H2 2017
  • High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • High-Grade Glioma - Pipeline by Sanofi, H2 2017
  • High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H2 2017
  • High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • High-Grade Glioma - Pipeline by Targepeutics Inc, H2 2017
  • High-Grade Glioma - Pipeline by Tocagen Inc, H2 2017
  • High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H2 2017
  • High-Grade Glioma - Dormant Projects, H2 2017
  • High-Grade Glioma - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for High-Grade Glioma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top